Sugi Predict

Sugi Predict / Compounds / SCHEMBL21808282

SCHEMBL21808282

SCHEMBL21808282

CC(C)C(=O)N1CCC(n2cc(B3OC(C)(C)C(C)(C)O3)cn2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.40
▸ LRRK2 Q5S007 1/20 0.38
▸ KDM5A P29375 2/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ ACVR1 Q04771 1/20 0.37
▸ USP30 Q70CQ3 1/20 0.36
▸ JAK1 P23458 5/20 0.34
▸ JAK3 P52333 5/20 0.34
▸ TYK2 P29597 4/20 0.34
▸ JAK2 O60674 2/20 0.34
▸ OGA O60502 2/20 0.33
▸ FAAH O00519 1/20 0.33
▸ MAPK8 P45983 1/20 0.33
▸ MAPK9 P45984 1/20 0.33
▸ MAPK10 P53779 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ DDB1 Q16531 1/20 0.33
▸ CRBN Q96SW2 1/20 0.33
▸ FLT4 P35916 1/20 0.33
▸ CLK2 P49760 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL320321 0.87 FFAR1 (0.42) FFAR1KDM5AUSP30JAK1JAK3
SCHEMBL658691 0.87 FFAR1 (0.42) FFAR1ACVR1JAK1JAK3TYK2
SCHEMBL2329051 0.86 JAK1 (0.43) FFAR1KDM5AFGFR1USP30JAK1
SCHEMBL661896 0.86 FFAR1 (0.41) FFAR1LRRK2KDM5AUSP30JAK1
SCHEMBL2750019 0.86 FFAR1 (0.41) FFAR1KDM5AUSP30JAK1JAK3
SCHEMBL23211127 0.83 FFAR1 (0.41) FFAR1KDM5AUSP30JAK1JAK3
SCHEMBL16342703 0.83 FFAR1 (0.41) FFAR1KDM5AUSP30JAK1JAK3
SCHEMBL23211118 0.83 FFAR1 (0.41) FFAR1KDM5AUSP30JAK1JAK3
SCHEMBL661092 0.82 FFAR1 (0.41) FFAR1OGAFLT4CLK2CLK3
SCHEMBL28649940 0.82 FFAR1 (0.46) FFAR1LRRK2USP30OGAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441731-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2025-10-14 — — US disclosed
EP-3856348-B1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS INCYTE CORP (US) 2024-01-03 — — EP disclosed
US-11111247-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2021-09-07 — — US disclosed
US-20200095250-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200095250-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF ALK, FGFR1, FGFR2 FFAR1 1535/4885LRRK2 1163/4885KDM5A 821/4885
US-12441731-B2 Pyrazolopyrimidine compounds and uses thereof ALK, FGFR1, FGFR2 FFAR1 1535/4885LRRK2 1163/4885KDM5A 821/4885
US-11111247-B2 Pyrazolopyrimidine compounds and uses thereof ALK, FGFR1, FGFR2 FFAR1 1535/4885LRRK2 1163/4885KDM5A 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.